Clinical Trial Update: A Study of Hetrombopag Combined With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CTIT) in Solid Tumor Patients. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating hetrombopag in combination with recombinant human thrombopoietin (rhTPO) for cancer therapy-induced thrombocytopenia in pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Therapy-induced Thrombocytopenia

Drugs mentioned

• Hetrombopag (hetrombopag)
• rhTPO (recombinant human thrombopoietin) (recombinant human thrombopoietin)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Cancer Therapy-induced Thrombocytopenia (CTIT) | Phase 2 | Status: NOT_YET_RECRUITING